
After receiving 4.8 mg of survodutide weekly for 46 weeks, more than half of trial participants achieved weight loss of 15% or more.

Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.

What We’re Reading: Low Rates of COVID-19 Boosters in Nursing Homes; Racial Discrimination in Health Care; New Obesity Treatment

After receiving 4.8 mg of survodutide weekly for 46 weeks, more than half of trial participants achieved weight loss of 15% or more.

Overall, home visitation staff support the use of technology-enhanced educational tools in conjunction with home visits to promote positive weight outcomes.

Independent FDA panel advises that the next round of COVID-19 vaccines only target XBB strains; the American Medical Association (AMA) says that only using body mass index (BMI) is not enough to evaluate health; teens with severe obesity look to controversial surgery and weight-loss drugs.

Type 2 diabetes drug tirzepatide (Mounjaro) helped some individuals lose nearly 16% of their body weight; some vital drugs have been sporadically in shortage for over 8 years; a bacterial outbreak of klebsiella claimed 4 lives and infected 31 people in a Seattle hospital.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
